Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 856704, 7 pages
http://dx.doi.org/10.1155/2015/856704
Research Article

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis

1Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, 415 Fengyang Road, Shanghai 200003, China
2Peking University People’s Hospital and Peking University Institute of Hematology, No. 11 Xizhimen South Street, Beijing 100044, China
3Department of Hematology, Beijing Chaoyang Hospital, Capital Medical University, 8 Workers Stadium South Road, Beijing 100020, China

Received 23 July 2015; Accepted 13 September 2015

Academic Editor: Abdel Kareem Azab

Copyright © 2015 Jing Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Rajkumar, “Treatment of multiple myeloma,” Nature Reviews Clinical Oncology, vol. 8, no. 8, pp. 479–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Kyle and S. V. Rajkumar, “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma,” Leukemia, vol. 23, no. 1, pp. 3–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. G. Durie and S. E. Salmon, “A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting,” Cancer, vol. 36, no. 3, pp. 842–854, 1975. View at Publisher · View at Google Scholar
  4. P. R. Greipp, J. S. Miguel, B. G. M. Dune et al., “International staging system for multiple myeloma,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3412–3420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Turesson, R. Velez, S. Y. Kristinsson, and O. Landgren, “Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 830–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Kastritis, K. Zervas, A. Symeonidis et al., “Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG),” Leukemia, vol. 23, no. 6, pp. 1152–1157, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Dimopoulos, E. Kastritis, E. Michalis et al., “The international scoring system (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function,” Annals of Oncology, vol. 23, no. 3, pp. 722–729, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S.-H. Yang, H.-W. Teng, Y.-C. Hong et al., “International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents,” Annals of Hematology, vol. 91, no. 1, pp. 93–102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. K. C. Anderson, M. Alsina, W. Bensinger et al., “Multiple myeloma, version 1.2013: featured updates to the NCCN guidelines,” Journal of the National Comprehensive Cancer Network, vol. 11, no. 1, pp. 11–17, 2013. View at Google Scholar · View at Scopus
  10. P. Moreau, J. San Miguel, H. Ludwig et al., “Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 24, no. 6, Article ID mdt297, pp. 133–137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. M. A. Dimopoulos, E. Kastritis, S. Delimpasi et al., “Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era,” European Journal of Haematology, vol. 89, no. 1, pp. 10–15, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Gay, A. Larocca, P. Wijermans et al., “Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients,” Blood, vol. 117, no. 11, pp. 3025–3031, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Zou, M. Lin, Z. Sheng, and S. Niu, “Bortezomib and lenalidomide as front-line therapy for multiple myeloma,” Leukemia and Lymphoma, vol. 55, no. 9, pp. 2024–2031, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Avet-Loiseau, X. Leleu, M. Roussel et al., “Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p),” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4630–4634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Jagannath, P. G. Richardson, P. Sonneveld et al., “Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials,” Leukemia, vol. 21, no. 1, pp. 151–157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Neben, H. M. Lokhorst, A. Jauch et al., “Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p,” Blood, vol. 119, no. 4, pp. 940–948, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Mikhael, D. Dingli, and V. Roy, “Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines,” Mayo Clinic Proceedings, vol. 88, no. 4, pp. 360–376, 2013. View at Publisher · View at Google Scholar
  19. A. Dispenzieri, R. Kyle, G. Merlini et al., “International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders,” Leukemia, vol. 23, no. 2, pp. 215–224, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Fonseca, B. Barlogie, R. Bataille et al., “Genetics and cytogenetics of multiple myeloma: a workshop report,” Cancer Research, vol. 64, no. 4, pp. 1546–1558, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Corso, M. Galli, S. Mangiacavalli et al., “Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma,” American Journal of Hematology, vol. 87, no. 2, pp. 150–154, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Avet-Loiseau, B. G. M. Durie, M. Cavo et al., “Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project,” Leukemia, vol. 27, no. 3, pp. 711–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Palumbo, H. Avet-Loiseau, S. Oliva et al., “Revised international staging system for multiple myeloma: a report from International Myeloma Working Group,” Journal of Clinical Oncology, 2015. View at Publisher · View at Google Scholar